A Randomized, Placebo-controlled Trial of DAPAgliflozin (DAPA) for Cardiovascular Risk Reduction in the Postpartum Period of Hypertensive Pregnancies (HP)
A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 200 participants.
Also called NCT06785116
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 200 participants
- Sponsor
- Registry
-
NCT06785116
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States
- Registry status
- Recruiting
Technical summary
Registry record NCT06785116. Randomized; quadruple masking; primary purpose treatment. Start 2025-03-02 (actual); primary completion 2028-08 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Randomized, Placebo-controlled Trial of DAPAgliflozin (DAPA) for Cardiovascular Risk Reduction in the Postpartum Period of Hypertensive Pregnancies (HP)
- Acronym
- DAPA-HP
- Condition
- Gestational Hypertension
- Condition
- Hypertension in Pregnancy
- Condition
- Pre-Eclampsia
- Condition
- Superimposed Pre-Eclampsia
- Condition
- Cardiovascular Complication
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Dapagliflozin 10mg Tab
- Lead sponsor
- University of Michigan
- Collaborator
- Society for Maternal-Fetal Medicine Foundation
- Collaborator
- American Association of Obstetricians and Gynecologists Foundation
Record details
- Record id
cardio:ct-nct06785116- Content hash
f7ea1fc32310902174453f7344a9d8f2bebf9b83a2ccd014376d85e096fd08ff